The ocular surface最新文献

Tear Fluid Derived Extracellular Vesicles for New Biomarker Discovery. 泪液衍生的细胞外囊泡：发现新的生物标志物。

The ocular surface Pub Date : 2025-05-12 DOI: 10.1016/j.jtos.2025.05.001

Natalie Phan, Yi Li, Menglu Yang, Fei Liu

引用次数: 0

Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid. Janus激酶抑制剂治疗类天疱疮难治性结膜炎。

The ocular surface Pub Date : 2025-05-12 DOI: 10.1016/j.jtos.2025.05.002

Celine Nguyen, Ebuka Eziama, Arturo R Dominguez, Jennifer Cao

{"title":"Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid.","authors":"Celine Nguyen, Ebuka Eziama, Arturo R Dominguez, Jennifer Cao","doi":"10.1016/j.jtos.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.jtos.2025.05.002","url":null,"abstract":"Objective: To evaluate the efficacy of Janus kinase inhibitor (JAKinib) therapy in managing cicatrizing conjunctivitis associated with ocular cicatricial pemphigoid (OCP) and mucous membrane pemphigoid with ocular involvement (ocMMP).Methods: Retrospective chart review of patients with cicatrizing conjunctivitis secondary to OCP or ocMMP who underwent treatment with JAKinibs at a tertiary academic medical center from August 2015 to November 2024 for minimum follow-up of six months. Collected data included demographics, Foster stage of cicatrization, and treatment course.Results: Thirty-two patients met inclusion criteria: 23 (71.9%) with OCP and 9 (28.1%) with ocMMP. 96.9% of patients demonstrated clinical improvement within twelve months of treatment initiation. Best response achieved were as follows: 1 (3.1%) no response, 17 (53.1%) partial response, 14 (43.8%) complete clinical remission, and 12 (37.5%) steroid-free remission. The mean time to partial response, complete clinical remission, steroid-free remission was 3.1 ± 1.8 (range, 0.9-8.3), 7.8 ± 3.3 months (range, 2.3-14.7 months), and 10.3 ± 7.4 months, (range, 2.3-31.4 months), respectively. Relapse in disease activity occurred in 8/32 (25.0%) of patients. Side effects occurred in 8/32 (25.0%) of patients. Four patients (12.5%) discontinued therapy due to severe adverse events, including transient ischemic attack, pulmonary embolism, pyelonephritis, and cholecystitis. There was a significant association between lower Foster cicatrization stages and achieving remission (U = 630.0, p = 0.0036), with a rank-biserial correlation of 0.72.Conclusions: JAK inhibitor therapy demonstrates efficacy in the management of recalcitrant cicatrizing conjunctivitis associated with pemphigoid. These findings highlight JAK inhibitors as a promising therapeutic option for refractory cases.","PeriodicalId":94247,"journal":{"name":"The ocular surface","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Reply to Prof. Jacqueline Tan's letter. Efficacy of eyelid warming devices as a first-step treatment in meibomian gland dysfunction: A systematic review with meta-analysis. 2025; 37:33-46. 眼睑温热装置作为睑板腺功能障碍第一步治疗的疗效：一项系统综述和meta分析。

The ocular surface Pub Date : 2025-04-17 DOI: 10.1016/j.jtos.2025.04.002

Ballesteros-Sánchez Antonio, Carlos Rocha-de-Lossada, José-María Sánchez-González

引用次数: 0

Re: Significant errors in the paper by Ballesteros-Sánchez A, Rocha-de-Lossada C and Sánchez-González J. Efficacy of eyelid warming devices as first-step treatment in meibomian gland dysfunction: A systematic review with meta-analysis. 2025; 37:33–46 回复：Ballesteros-Sánchez A、Rocha-de-Lossada C和Sánchez-González j的论文存在显著错误。眼睑温热装置作为睑板腺功能障碍第一步治疗的疗效：一项meta分析的系统综述。2025年;37:33-46

The ocular surface Pub Date : 2025-04-11 DOI: 10.1016/j.jtos.2025.04.003

Jacqueline Tan

引用次数: 0

Acanthamoeba keratitis treatment outcomes compared for drug delivery by protocol versus physician's individualised treatment. 棘阿米巴角膜炎的治疗结果比较方案给药与医生个体化治疗。

The ocular surface Pub Date : 2025-04-07 DOI: 10.1016/j.jtos.2025.03.008

John K G Dart, Vincenzo Papa, Paolo Rama, Karl Anders Knutsson, Saj Ahmad, Scott Hau, Sara Sanchez, Antonella Franch, Federica Birattari, Pia Leon, Adriano Fasolo, Ewa Mrukwa-Kominek, Katarzyna Jadczyk-Sorek, Fiona Carley, Hossain Parwez, Darwin C Minassian

{"title":"Acanthamoeba keratitis treatment outcomes compared for drug delivery by protocol versus physician's individualised treatment.","authors":"John K G Dart, Vincenzo Papa, Paolo Rama, Karl Anders Knutsson, Saj Ahmad, Scott Hau, Sara Sanchez, Antonella Franch, Federica Birattari, Pia Leon, Adriano Fasolo, Ewa Mrukwa-Kominek, Katarzyna Jadczyk-Sorek, Fiona Carley, Hossain Parwez, Darwin C Minassian","doi":"10.1016/j.jtos.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.jtos.2025.03.008","url":null,"abstract":"Purpose: To compare Acanthamoeba keratitis (AK) outcomes for treatment delivered using a detailed protocol versus physician's individualised treatment.Methods: This double cohort study compared the outcomes of these different delivery methods for PHMB 0.02% and diamidine 0.1% dual therapy. The primary outcome was the medical cure rate without surgery within 12 months (MCR_12) and the secondary was visual acuity. Any change of treatment, any surgery, or treatment for >12 months was a failure. Outcomes were both unadjusted and adjusted, using multivariable analysis, for baseline differences affecting outcomes. Patients were from two centres in Milan and London treated at different times; the individualised cohort (1991-2012) and per-protocol cohort (2017-2021).Results: The individualised cohort included 96 and the per-protocol 47 patients. Both unadjusted and adjusted results were similar. The unadjusted outcomes for both centres combined showed significantly improved outcomes for per-protocol treatment with a 1.59-fold improvement in MCR_12 (95% CI 1.40 - 1.80, p < 0.001) and a 2.1-fold increase in visual acuity ≥ 20/25 (95% CI 1.34 - 3.29, p < 0.001). Amongst potential confounding factors examined, neither baseline AK disease stage, treatment centre nor the type of diamidine significantly influenced outcomes.Conclusions: This study shows significant advantages for the use of protocol delivered versus individualised treatment for AK. The use of evidence-based treatment delivery protocols, like the one used here for AK, might improve outcomes for all causes of microbial keratitis and could offer practitioners and patients the benefit of having an easy-to-follow drug delivery protocol, with known outcomes.","PeriodicalId":94247,"journal":{"name":"The ocular surface","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial. AZR-MD-001 0.5%硫化硒眼膏治疗隐形眼镜不适：一项对照、随机、临床试验。

The ocular surface Pub Date : 2024-12-28 DOI: 10.1016/j.jtos.2024.12.009

Fiona Stapleton, Mark Hinds, Jacqueline Tan, Lyndon Jones, Robin Chalmers, Charles Bosworth, Yair Alster

{"title":"AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial.","authors":"Fiona Stapleton, Mark Hinds, Jacqueline Tan, Lyndon Jones, Robin Chalmers, Charles Bosworth, Yair Alster","doi":"10.1016/j.jtos.2024.12.009","DOIUrl":"10.1016/j.jtos.2024.12.009","url":null,"abstract":"Background: Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers. The current study evaluated the efficacy and safety of AZR in participants with CLD and concomitant MGD.Methods: Adults with CLD (Contact Lens Dry Eye Questionnaire-8 >12, range 0-37) and MGD (Meibomian Gland Secretion Score [MGS] ≤12, range 0-45) were randomized (1:1) to AZR:vehicle applied twice-weekly in a three-month multicenter, prospective, double-masked study. Endpoints included difference in change from baseline (CFB) in the number of Meibomian Glands Yielding Liquid Secretion (MGYLS), MGS, the ability to wear their lenses as long as desired, and safety.Results: At Month 3, AZR (n = 34) significantly increased the MGYLS and MGS versus vehicle (n = 33), with least squares mean difference (LSMD) CFB in MGYLS of 5.0 (SE = 0.47) for AZR and 1.6 (0.45) for vehicle, P < 0.0001; MGS of 13.8 (SE = 0.67) for AZR and 3.8 (SE = 0.68) for vehicle, P < 0.0001. Significantly more participants treated with AZR were able to wear lenses as long as desired (43% vs. 6%, P = 0.0023). The most common treatment-emergent adverse event (TEAE) was eye irritation (61.8% AZR; 0% vehicle). All TEAEs related to treatment were mild/moderate, transient, and did not result in discontinuation.Conclusion: AZR-MD-001 0.5% significantly improved MGD signs and hours of comfortable CL wear, demonstrating good efficacy, safety, and tolerability in those with CLD.","PeriodicalId":94247,"journal":{"name":"The ocular surface","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Readership awareness series – Paper 9: Retraction of a publication 读者意识系列 - 文件 9：撤回出版物

The ocular surface Pub Date : 2024-01-17 DOI: 10.1016/j.jtos.2024.01.008

Mohammad Javed Ali, Ali Djalilian

引用次数: 0